CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
CGT003 (E2F Duplex Decoy)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00042081
NCT00042081Phase 3Completed
CompareCT.gov

A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures

Anesiva, Inc.·interventional·Posted Jul 24, 2002·Updated May 5, 2006

In Brief

A Phase 3 clinical trial evaluating CGT003 (E2F Duplex Decoy) for Coronary Artery Disease. Completed, across 154 sites.

Detailed Summary

The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 24, 2002
Enrollment StartJul 1, 2002
Study CompletionFeb 1, 2005
TodayJul 2, 2026
Posted 23.9 years ago

Interventions

CGT003 (E2F Duplex Decoy)drug